Abstract
Prion diseases are fatal neurodegenerative disorders with no effective therapy. A hallmark of prion disease is the conversion of the normal cellular form of prion protein PrPC into a disease-associated isoform PrPSc. The authors recently have shown that a tyrosine kinase inhibitor, imatinib mesylate, induces clearance of PrPSc via specific inhibition of c-Abl in prion-infected cell culture models. In this study, the authors assessed the in vivo effects of imatinib mesylate on prion disease using a scrapie-infected mouse model and further investigated prion infectivity of the drug-treated scrapie-infected neuroblastoma (ScN2a) cells. The authors found that imatinib mesylate abolished prion infectivity to almost undetectable level in ScN2a cells and the level of PrPSc was significantly decreased by the drug in scrapie-infected mouse spleens as well as in ScN2a cells. Moreover, the drug treatment at an early phase of peripheral scrapie infection delayed the appearance of PrPSc in the central nervous system (CNS) and onset of clinical disease in mice. However, neither intraperitoneal nor intracerebroventricular delivery of the drug exerted any PrPSc clearance effect in the CNS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aguzzi A, Heikenwalder M (2005). Prions, cytokines, and chemokines: a meeting in lymphoid organs. Immunity 22: 145–154.
Blattler T, Brandner S, Raeber AJ, Klein MA, Voigtlander T, Weissmann C, Aguzzi A (1997). PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature 389: 69–73.
Brain J, Saksena A, Laneuville P (2002). The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice. Leuk Res 26: 1011–1016.
Buday L (1999). Membrane-targeting of signalling molecules by SH2/SH3 domain-containing adaptor proteins. Biochim Biophys Acta 1422: 187–204.
Budka H (2003). Neuropathology of prion diseases. Br Med Bull 66: 121–130.
Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C (1993). Mice devoid of PrP are resistant to scrapie. Cell 73: 1339–1347.
Bujassoum S, Rifkind J, Lipton JH (2004). Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma 45: 401–403.
Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002). Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493–502.
Cashman NR, Caughey B (2004). Prion diseases—close to effective therapy? Nat Rev Drug Discov 3: 874–884.
Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, Raymond L, Favara C, Baron G, Priola S, Caughey B, Masliah E, Oldstone M (2005). Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308: 1435–1439.
Criado JR, Sanchez-Alavez M, Conti B, Giacchino JL, Wills DN, Henriksen SJ, Race R, Manson JC, Chesebro B, Oldstone MB (2005). Mice devoid of prion protein have cognitive deficits that are rescued by reconstitution of PrP in neurons. Neurobiol Dis 19: 255–265.
Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE (2005). hOCT 1 and resistance to imatinib. Blood 106: 1133–1134.
Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF (2003). Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304: 1085–1092.
Decaudin D, de Cremoux P, Sastre X, Judde JG, Nemati F, Tran-Perennou C, Freneaux P, Livartowski A, Pouillart P, Poupon MF (2005). In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. Int J Cancer 113: 849–856.
Doh-ura K, Ishikawa K, Murakami-Kubo I, Sasaki K, Mohri S, Race R, Iwaki T (2004). Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 78: 4999–5006.
Ertmer A, Gilch S, Yun SW, Flechsig E, Klebl B, Stein-Gerlach M, Klein MA, Schatzl HM (2004). The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J Biol Chem 279: 41918–41927.
Glatzel M, Heppner FL, Albers KM, Aguzzi A (2001). Sympathetic innervation of lymphoreticular organs is rate limiting for prion neuroinvasion. Neuron 31: 25–34.
Green RM, Lo K, Sterritt C, Beier DR (1999). Cloning and functional expression of a mouse liver organic cation transporter. Hepatology 29: 1556–1562.
Heikenwalder M, Zeller N, Seeger H, Prinz M, Klohn PC, Schwarz P, Ruddle NH, Weissmann C, Aguzzi A (2005). Chronic lymphocytic inflammation specifies the organ tropism of prions. Science 307: 1107–1110.
Honey K, Rudensky AY (2003). Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 3: 472–482.
Jones SB, Lu HY, Lu Q (2004). Abl tyrosine kinase promotes dendrogenesis by inducing actin cytoskeletal rearrangements in cooperation with Rho family small GTPases in hippocampal neurons. J Neurosci 24: 8510–8521.
Jonker JW, Schinkel AH (2004). Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 308: 2–9.
Kaeser PS, Klein MA, Schwarz P, Aguzzi A (2001). Efficient lymphoreticular prion propagation requires PrP(c) in stromal and hematopoietic cells. J Virol 75: 7097–7106.
Kimberlin RH, Walker CA (1988). Incubation periods in six models of intraperitoneally injected scrapie depend mainly on the dynamics of agent replication within the nervous system and not the lymphoreticular system. J Gen Virol 69(Pt 12): 2953–2960.
Klein MA, Kaeser PS, Schwarz P, Weyd H, Xenarios I, Zinkernagel RM, Carroll MC, Verbeek JS, Botto M, Walport MJ, Molina H, Kalinke U, Acha-Orbea H, Aguzzi A (2001). Complement facilitates early prion pathogenesis. Nat Med 7: 488–492.
Leis JF, Stepan DE, Curtin PT, Ford JM, Peng B, Schubach S, Druker BJ, Maziarz RT (2004). Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 45: 695–698.
Li A, Harris DA (2005). Mammalian prion protein suppresses Bax-induced cell death in yeast. J Biol Chem 280: 17430–17434.
Luhr KM, Nordstrom EK, Low P, Ljunggren HG, Taraboulos A, Kristensson K (2004). Scrapie protein degradation by cysteine proteases in CD11c+ dendritic cells and GT1-1 neuronal cells. J Virol 78: 4776–4782.
Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV (2003). MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101: 2368–2373.
Montrasio F, Frigg R, Glatzel M, Klein MA, Mackay F, Aguzzi A, Weissmann C (2000). Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science 288: 1257–1259.
Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, Launay JM, Kellermann O (2000). Signal transduction through prion protein. Science 289: 1925–1928.
Netzer WJ, Dou F, Cai D, Veach D, Jean S, Li Y, Bornmann WG, Clarkson B, Xu H, Greengard P (2003). Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A 100: 12444–12449.
Nico PB, de-Paris F, Vinade ER, Amaral OB, Rockenbach I, Soares BL, Guarnieri R, Wichert-Ana L, Calvo F, Walz R, Izquierdo I, Sakamoto AC, Brentani R, Martins VR, Bianchin MM (2005). Altered behavioural response to acute stress in mice lacking cellular prion protein. Behav Brain Res 162: 173–181.
Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, Mehlhorn IR, Legname G, Wormald MR, Rudd PM, Dwek RA, Burton DR, Prusiner SB (2001). Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412: 739–743.
Prinz M, Heikenwalder M, Junt T, Schwarz P, Glatzel M, Heppner FL, Fu YX, Lipp M, Aguzzi A (2003). Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature 425: 957–962.
Prusiner SB (1998). Prions. Proc Natl Acad Sci U S A 95: 13363–13383.
Roucou X, Gains M, LeBlanc AC (2004). Neuroprotective functions of prion protein. J Neurosci Res 75: 153–161.
Safar JG, DeArmond SJ, Kociuba K, Deering C, Didorenko S, Bouzamondo-Bernstein E, Prusiner SB, Tremblay P (2005). Prion clearance in bigenic mice. J Gen Virol 86: 2913–2923.
Schmitt A, Mossner R, Gossmann A, Fischer IG, Gorboulev V, Murphy DL, Koepsell H, Lesch KP (2003). Organic cation transporter capable of transporting serotonin is up-regulated in serotonin transporter-deficient mice. J Neurosci Res 71: 701–709.
Schwartzberg PL, Stall AM, Hardin JD, Bowdish KS, Humaran T, Boast S, Harbison ML, Robertson EJ, Goff SP (1991). Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 65: 1165–1175.
Spielhaupter C, Schatzl HM (2001). PrPC directly interacts with proteins involved in signaling pathways. J Biol Chem 276: 44604–44612.
Supattapone S, Nguyen HO, Cohen FE, Prusiner SB, Scott MR (1999). Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci U S A 96: 14529–14534.
Supattapone S, Wille H, Uyechi L, Safar J, Tremblay P, Szoka FC, Cohen FE, Prusiner SB, Scott MR (2001). Branched polyamines cure prion-infected neuroblastoma cells. J Virol 75: 3453–3461.
Takayama N, Sato N, O’Brien SG, Ikeda Y, Okamoto S (2002). Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 119: 106–108.
Thomas J, Wang L, Clark RE, Pirmohamed M (2004). Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104: 3739–3745.
Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC (1991). Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65: 1153–1163.
Wang H, Cheng F, Cuenca A, Horna P, Zheng Z, Bhalla K, Sotomayor EM (2005). Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 105: 1135–1143.
Weissmann C, Aguzzi A (2005). Approaches to therapy of prion diseases. Annu Rev Med 56: 321–344.
Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr (2003). The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 101: 5010–5013.
Woodring PJ, Hunter T, Wang JY (2003). Regulation of Factin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci 116: 2613–2626.
Yun SW, Gerlach M, Riederer P, Klein MA (2006). Oxidative stress in the brain at early preclinical stages of mouse scrapie. Exp Neurol 201: 90–98.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by the Bavarian research cooperation (FORPRION) granted by the Ministry of Science, Research and Art of Bavaria. E.F. is supported by the Emmy-Noether program of the German Research Foundation.
Rights and permissions
About this article
Cite this article
Yun, SW., Ertmer, A., Flechsig, E. et al. The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. Journal of NeuroVirology 13, 328–337 (2007). https://doi.org/10.1080/13550280701361516
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1080/13550280701361516